Vitasora Completes A$11M Raise, Eyes FY2026 Cash Flow Breakeven

Capital Raise Completion and Financial Strengthening

Vitasora Health Limited has successfully completed an A$11 million capital raise, including a significant A$6.75 million cornerstone investment. This milestone strengthens the company’s financial position, providing a robust foundation to execute its US growth strategy. The funds were raised through a combination of placements to new and existing investors, with the final share issuance expected imminently.

Operational Momentum and Expanding Patient Base

Operationally, Vitasora is gaining traction with patient programs growing to 22,458, marking a 7.6% increase quarter-on-quarter despite the conclusion of a legacy contract. Key partnerships are driving this growth, including a collaboration with Iris Medical Group, which manages over 12,000 patients across the southeastern US. Since late 2025, approximately 1,000 patients have been enrolled in this program, with revenue impacts anticipated in the March quarter.

Further expansion includes Tampa Family Health Centers, now offering both Medicare and Medicaid Chronic Care Management and Remote Patient Monitoring services to around 7,000 patients. Additionally, Family Care in West Virginia onboarded 1,700 patients under an enhanced enrolment framework, reflecting Vitasora’s scaling capabilities across diverse US markets.

Strategic Focus on Automation and Medicaid Programs

The capital raise enables Vitasora to invest in automation and AI-driven enrolment processes, aiming to improve operational efficiency. The company is also focused on ramping up Medicaid and fee-for-service programs, including those with Iris Health, Tampa Family Health Centers, and Family Care. These initiatives are critical to achieving the company’s goal of cash flow breakeven by the end of FY2026, supported by a disciplined approach to investment and scaling.

Outlook and Market Positioning

Looking ahead, Vitasora is well-positioned to capitalise on growing demand for Connected Care services in the US healthcare sector. The company’s proprietary technology, including the FDA-approved wheezo® device for respiratory monitoring, differentiates it in a competitive market. With a strengthened balance sheet and expanding contracted programs, Vitasora aims to build a scalable and sustainable platform that delivers personalised, data-driven care to chronic disease patients.

The Board remains confident in the company’s strategy and funding outlook, anticipating continued operational progress and improved enrolment conversion rates throughout 2026.